KEDI Global Longevity Bio Index

FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.

Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled

Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.

Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.

GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.

Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.

RELX is scheduled to release its earnings report for the six months ending June 30, 2026, expected.

Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.

Q2 2026 earnings release on July 20, 2026, is a recurring event with high potential for price impact and is scheduled.

Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.

FDA target action (PDUFA) date for olezarsen in severe hypertriglyceridemia (sHTG) on 2026-06-30. Priority Review for first treatment to reduce acute pancreatitis attacks; peak sales estimated >$3B, justifying high importance scheduled.

FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.

An FDA advisory committee meeting is scheduled for 2026-06-18 to discuss the safety and effectiveness of Moderna's seasonal flu vaccine candidate (mFlusia/mRNA-1010), which is estimated to cause a ≥5% price impact scheduled.

Quarterly cash dividend of $0.43 per share, with an ex-dividend date of June 15, 2026. Low importance is estimated as routine dividends typically result in a minor price adjustment of ≥1%, scheduled.

Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.

Regeneron will hold its 2026 Annual Meeting of Shareholders virtually on June 12, 2026, scheduled.

Sanofi launched its annual global employee stock purchase plan, 'Action 2026', with the subscription period starting on June 9, 2026.

Novo Nordisk to host an R&D investor event to discuss data from the ADA 2026 Scientific Sessions, including Phase 3 results for CagriSema on 2026-06-07; High importance is estimated as Phase 3 data for key pipeline assets typically drives >10% price movement, scheduled.

Announced on 2026-06-04 that the U.S. FDA granted Breakthrough Therapy Designation for salanersen. A Medium importance is estimated as this designation significantly accelerates the regulatory path for a key asset, estimated.

On June 4, 2026, Regeneron announced an expanded collaboration with CytomX Therapeutics to develop cancer therapies; estimated >5% price impact due to the multi-billion dollar deal potential, expected.

Partner Innovent Biologics announced that IBI343 (arcotatug tavatecan) met its primary endpoint in a Phase 3 trial on June 4, 2026; a medium market impact is estimated based on the clinical significance of the results. expected

Teva announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, in several European markets including France, Germany, Spain, and The Netherlands, which began in May 2026.

Announced a strategic collaboration with Inceptive Nucleics on June 4, 2026, to use AI in the discovery of RNAi therapies. The deal is valued at up to $2 billion, including a $30 million upfront payment, and the stock rose approximately 4%.

Announced the pricing of a €950 million senior notes offering due 2033 at 4.625% interest on 2026-06-04 to refinance existing debt.

Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.

Published on 2026-06-04 final Phase III results for Vanrafia in The Lancet. Low importance estimated as the positive data supports existing market expectations, with an expected impact of approximately 1%.

Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.

Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.

Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.

Novo Nordisk to launch the Wegovy pill in the United Arab Emirates on 2026-06-03; Medium importance is estimated as new market entries for blockbuster drugs typically impact price by >=5%, scheduled.

The U.S. FDA ordered Takeda to add a boxed warning to Adzynma on June 3, 2026; a medium market impact is estimated due to potential safety concerns affecting sales. expected

The company's stock price reached a 52-week low of $283.58 on June 3, 2026, marking a decline of nearly 43% from its 52-week high.

Appointed oncology leaders Dr. Thomas Lynch and Dr. Eric Rubin to the company's board of directors.

Presented positive final results from the Phase III SERENA-6 trial for camizestrant in breast cancer at the ASCO 2026 Annual Meeting, showing a 37% reduction in risk of second disease progression or death. High importance estimated due to significant clinical success in a major indication.

Bristol Myers Squibb and partner SystImmune announced on 2026-06-02 that their ADC iza-bren showed significant Phase 3 results in TNBC and ESCC. This major clinical success is estimated to have a >10% price impact expected.

The European Commission approved AQUIPTA (atogepant) for the acute treatment of migraine in adults on 2026-06-02; analysts forecast this market expansion will result in a price impact of ≥5% expected.

European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.

Announced that the CARES Phase III clinical program for anselamimab, a treatment for light chain amyloidosis, did not meet its primary endpoint in the overall patient population. High importance estimated due to the failure of a late-stage clinical trial.

Moderna and Merck presented positive 5-year follow-up data for their personalized cancer vaccine (intismeran autogene/mRNA-4157) in combination with Keytruda for high-risk melanoma at the 2026 ASCO Annual Meeting on 2026-06-01. The 49% reduction in recurrence risk is estimated to cause a ≥10% price impact scheduled.

Announced on June 1, 2026, that the Phase 3 LITESPARK-012 study of a Keytruda-based triplet therapy in first-line advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints.

Announced with partner UCB on 2026-06-01 that full results from the Phase 3 PHOENYCS GO trial of dapirolizumab pegol were published in The Lancet. A Low importance is estimated as journal publications usually have a limited impact on stock price, estimated.

The U.S. FDA accepted for Priority Review the sNDA for Camzyos on 2026-06-01. This regulatory milestone is estimated to have a >1% price impact expected.

On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.

On May 31, 2026, presented positive preliminary Phase 1/2 data for linvoseltamab at the ASCO annual meeting; estimated >5% price impact due to positive clinical results for a key pipeline drug, expected.

President Jesse Geiger retired, effective May 31, 2026.

Exelixis announced positive results from a subgroup analysis of the Phase 3 CABINET pivotal trial, showing its drug CABOMETYX® significantly reduced the risk of disease progression or death in patients with advanced neuroendocrine tumors (NET). The data was presented at the 2026 ASCO Annual Meeting. This pivotal trial success is significant for biotech valuation and is estimated to have a high market impact (≥10%) expected

Pfizer announced positive Phase 3 TALAPRO-3 trial results on 2026-05-30 for Talzenna plus Xtandi; Medium importance estimated due to significant reduction in disease progression risk.

Announced positive Phase 3 SUCCESSOR-2 trial results on 2026-05-29 showing a 52% reduction in disease progression risk for multiple myeloma. This breakthrough is estimated to have a >10% price impact expected.

Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.

Pfizer presented seven-year CROWN trial analysis for LORBRENA on 2026-05-29; Medium importance estimated as long-term survival data strengthens its competitive position.